Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Optimising urinary catecholamine metabolite diagnostics for neuroblastoma

YAH. Matser, IRN. Verly, M. van der Ham, MGM. de Sain-van der Velden, NM. Verhoeven-Duif, S. Ash, G. Cangemi, S. Barco, MB. Popovic, ABP. van Kuilenburg, GAM. Tytgat, SIOPEN Catecholamine Working Group

. 2023 ; 70 (6) : e30289. [pub] 20230403

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011228

INTRODUCTION: The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. METHODS: Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS). RESULTS: Catecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples (p > .08 and >.27 for all metabolites). The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p = .02). No differences were observed in metabolite levels between the two analysis methods. CONCLUSION: Catecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011228
003      
CZ-PrNML
005      
20230801132905.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.30289 $2 doi
035    __
$a (PubMed)37010353
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Matser, Yvette A H $u Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands $u Laboratory of Genetic Metabolic Diseases, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000271823202
245    10
$a Optimising urinary catecholamine metabolite diagnostics for neuroblastoma / $c YAH. Matser, IRN. Verly, M. van der Ham, MGM. de Sain-van der Velden, NM. Verhoeven-Duif, S. Ash, G. Cangemi, S. Barco, MB. Popovic, ABP. van Kuilenburg, GAM. Tytgat, SIOPEN Catecholamine Working Group
520    9_
$a INTRODUCTION: The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. METHODS: Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS). RESULTS: Catecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples (p > .08 and >.27 for all metabolites). The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p = .02). No differences were observed in metabolite levels between the two analysis methods. CONCLUSION: Catecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.
650    _2
$a lidé $7 D006801
650    _2
$a chromatografie kapalinová $x metody $7 D002853
650    12
$a tandemová hmotnostní spektrometrie $x metody $7 D053719
650    _2
$a kyselina homovanilová $x moč $7 D006719
650    _2
$a metanefrin $x moč $7 D008676
650    _2
$a kyselina vanilmandlová $x moč $7 D014642
650    12
$a neuroblastom $x diagnóza $7 D009447
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Verly, Iedan R N $u Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands $u Laboratory of Genetic Metabolic Diseases, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000167453360
700    1_
$a van der Ham, Maria $u Department of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a de Sain-van der Velden, Monique G M $u Department of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a Verhoeven-Duif, Nanda M $u Department of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a Ash, Shifra $u Ruth Rappaport Children's Hospital, Haifa, Israel
700    1_
$a Cangemi, Giuliana $u Central Laboratory of Analyses Chromatography and Mass Spectrometry Section, IRCCS Istituto Giannina Gaslini, Genoa, Italy
700    1_
$a Barco, Sebastiano $u Central Laboratory of Analyses Chromatography and Mass Spectrometry Section, IRCCS Istituto Giannina Gaslini, Genoa, Italy
700    1_
$a Popovic, Maja Beck $u University Hospital Lausanne, Lausanne, Switzerland
700    1_
$a van Kuilenburg, André B P $u Laboratory of Genetic Metabolic Diseases, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands $u Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands
700    1_
$a Tytgat, Godelieve A M $u Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands $1 https://orcid.org/0000000344520748
710    2_
$a SIOPEN Catecholamine Working Group
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 70, č. 6 (2023), s. e30289
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37010353 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132902 $b ABA008
999    __
$a ok $b bmc $g 1963553 $s 1197493
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 70 $c 6 $d e30289 $e 20230403 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options